Shorter door-to-balloon time, better long-term clinical outcomes in ST-segment elevation myocardial infarction patients: J-MINUET substudy.

Humans ST Elevation Myocardial Infarction / therapy Prospective Studies Time Factors Myocardial Infarction / therapy Percutaneous Coronary Intervention Treatment Outcome
Door-to-balloon time Long-term outcomes Primary percutaneous coronary intervention ST-segment elevation myocardial infarction

Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
06 2023
Historique:
received: 07 10 2022
revised: 26 12 2022
accepted: 30 12 2022
medline: 25 4 2023
pubmed: 4 2 2023
entrez: 3 2 2023
Statut: ppublish

Résumé

The impact of shorter door-to-balloon (DTB time on long-term outcomes in ST-segment elevation myocardial infarction (STEMI treated with primary percutaneous coronary intervention (PPCI has not been fully elucidated. We investigated 3283 consecutive patients with acute myocardial infarction selected from a prospective, nationwide, multicenter registry (J-MINUET database comprising 28 institutions in Japan between July 2012 and March 2014. Among the study population, we analyzed 1639 STEMI patients who had PPCI within 12 h of onset. Patients were stratified into four groups (DTB time < 45 min, 45-60 min, 61-90 min, >90 min. The primary endpoint was a composite of all-cause death, non-fatal MI, non-fatal stroke, cardiac failure, and urgent revascularization for unstable angina up to 3 years. We performed landmark analysis for incidence of the primary endpoint from 31 days to 3 years among the four groups. The primary endpoint rate from 31 days to 3 years increased significantly and time-dependently with DTB time (10.2 % vs. 15.3 % vs. 16.2 % vs. 19.3 %, respectively; log-rank p = 0.0129. Higher logarithm-transformed DTB time was associated with greater risk of a primary endpoint from 31 days to 3 years, and the increased number of adverse long-term clinical outcomes persisted even after adjusting for other independent variables. Shorter DTB time was associated with better long-term clinical outcomes in STEMI patients treated with PPCI in contemporary clinical practice. Further efforts to shorten DTB time are recommended to improve long-term clinical outcomes in STEMI patients. UMIN Unique trial Number: UMIN000010037.

Sections du résumé

BACKGROUND
The impact of shorter door-to-balloon (DTB time on long-term outcomes in ST-segment elevation myocardial infarction (STEMI treated with primary percutaneous coronary intervention (PPCI has not been fully elucidated.
METHODS
We investigated 3283 consecutive patients with acute myocardial infarction selected from a prospective, nationwide, multicenter registry (J-MINUET database comprising 28 institutions in Japan between July 2012 and March 2014. Among the study population, we analyzed 1639 STEMI patients who had PPCI within 12 h of onset. Patients were stratified into four groups (DTB time < 45 min, 45-60 min, 61-90 min, >90 min. The primary endpoint was a composite of all-cause death, non-fatal MI, non-fatal stroke, cardiac failure, and urgent revascularization for unstable angina up to 3 years. We performed landmark analysis for incidence of the primary endpoint from 31 days to 3 years among the four groups.
RESULTS
The primary endpoint rate from 31 days to 3 years increased significantly and time-dependently with DTB time (10.2 % vs. 15.3 % vs. 16.2 % vs. 19.3 %, respectively; log-rank p = 0.0129. Higher logarithm-transformed DTB time was associated with greater risk of a primary endpoint from 31 days to 3 years, and the increased number of adverse long-term clinical outcomes persisted even after adjusting for other independent variables.
CONCLUSION
Shorter DTB time was associated with better long-term clinical outcomes in STEMI patients treated with PPCI in contemporary clinical practice. Further efforts to shorten DTB time are recommended to improve long-term clinical outcomes in STEMI patients.
TRIAL REGISTRATION
UMIN Unique trial Number: UMIN000010037.

Identifiants

DOI: 10.1016/j.jjcc.2023.01.008 PMID: 36736534
pubmed: 36736534
pii: S0914-5087(23)00019-9
doi: 10.1016/j.jjcc.2023.01.008
pii:
doi:

Banques de données

UMIN-CTR
['UMIN000010037']

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

564-570

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests. Yukio Ozaki has received several research grants from Bayer Yakuhin, Ltd., Research Institute for Production Development, Daiichi-Sankyo Co., Ltd., and Dainippon Sumitomo Co., Ltd. Kazuo Kimura has received honoraria from AstraZeneca, Toa Eiyo Ltd., MSD K.K., Bayer Yakuhin, Ltd., and Daiichi-Sankyo Co., Ltd., and has received several research grants from MSD K.K., Daiichi-Sankyo Co., Ltd., Ono Pharmaceutical Co., Pfizer Japan Inc., Bayer Yakuhin Ltd., Takeda Pharmaceutical Co., Ltd., Boehringer Ingelheim Japan, Tanabe Mitsubishi, and Astellas Pharma Inc. Wataru Shimizu has received honoraria from Daiichi-Sankyo Co., Ltd., Boehringer Ingelheim Japan, Bayer Yakuhin Ltd., Bristol, and Ono Pharmaceutical Co., and has received several research grants from Daiichi-Sankyo Co., Ltd., Boehringer Ingelheim Japan, Ono Pharmaceutical Co., Otsuka Pharmaceutical Co., Eisai Co., Mitsubishi Tanabe Pharma Co., Asterllas Pharma Inc., and St Jude Medical. Yoshihiko Saito has received honoraria from Otsuka Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Co., Pfizer Japan Inc., and Novartis Pharma K.K., and has received several research grants from Takeda Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Ono Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Eisai Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Co., Ltd., and Boston Scientific Japan K.K. Toshiaki Mano has received a research grant from Abbot Vascular Japan. Kengo Tanabe has received honoraria from Abbot Vascular Japan, Mitsubishi Tanabe Pharma Co., and Daiichi Sankyo Co., Ltd. and has received several research grants from Kaneka and Terumo. Kenichi Tsujita has received honoraria from Amgen Astellas Bio Pharma K.K., Bayer Yakuhin, Ltd., Daiichi Sankyo Co., Ltd., MSD K.K., and Sanofi K.K., and has received several research grants from AstraZeneca K.K., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Boehringer Ingelheim Japan, Boston Scientific Japan K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Kowa Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., MSD K.K., Pfizer Japan Inc., Sanofi K.K., Shionogi & Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Masaharu Ishihara has received honoraria from Bayer Yakuhin Ltd., MSD K.K., Astra Zeneca, and Astellas Pharma Inc. and has received several research grants from Abbott Vascular Japan, Boston Scientific Japan K.K., Sanofi K.K., MSD K.K., Astellas Pharma Inc., Bayer Yakuhin Ltd., Pfizer, Daiichi Sankyo Co., Ltd., MID, and Goodman. No funders played any role in this study.

Auteurs

Ryota Nishio (R)

Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.

Manabu Ogita (M)

Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan. Electronic address: m-ogita@juntendo.ac.jp.

Satoru Suwa (S)

Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan.

Koichi Nakao (K)

Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.

Yukio Ozaki (Y)

Department of Cardiology, Fujita Health University Hospital, Toyoake, Japan.

Kazuo Kimura (K)

Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan.

Junya Ako (J)

Department of Cardiovascular Medicine, Kitasato University, Sagamihara, Japan.

Teruo Noguchi (T)

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Kazuteru Fujimoto (K)

Department of Cardiology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan.

Kazuoki Dai (K)

Department of Cardiology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.

Takashi Morita (T)

Division of Cardiology, Osaka General Medical Center, Osaka, Japan.

Wataru Shimizu (W)

Department of Cardiovascular Medicine, Nippon Medical School, Tokyo, Japan.

Yoshihiko Saito (Y)

Department of Cardiovascular Medicine, Nara Medical University, Kashihara, Japan.

Atsushi Hirohata (A)

Department of Cardiovascular Medicine, The Sakakibara Heart Institute of Okayama, Okayama, Japan.

Yasuhiro Morita (Y)

Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan.

Teruo Inoue (T)

Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.

Atsunori Okamura (A)

Department of Cardiology, Sakurabashi Watanabe Hospital, Osaka, Japan.

Toshiaki Mano (T)

Cardiovascular Center, Kansai Rosai Hospital, Amagasaki, Japan.

Minoru Wake (M)

Department of Cardiology, Okinawa Prefectural Chubu Hospital, Uruma, Japan.

Kengo Tanabe (K)

Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.

Yoshisato Shibata (Y)

Department of Cardiology, Miyazaki Medical Association Hospital, Miyazaki, Japan.

Hiroshi Tsutsui (H)

Department of Cardiovascular Medicine, Suwa Red Cross Hospital Hospital, Nagano, Japan.

Hiroshi Funayama (H)

Department of Integrated Medicine, Saitama Medical Center Jichi Medical University, Saitama, Japan.

Nobuaki Kokubu (N)

Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, Sapporo, Japan.

Ken Kozuma (K)

Department of Cardiology, Teikyo University, Tokyo, Japan.

Shirou Uemura (S)

Department of Cardiology, Kawasaki Medical School, Kurashiki, Japan.

Tetsuya Toubaru (T)

Department of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.

Keijiro Saku (K)

Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.

Shigeru Oshima (S)

Department of Cardiology, Gunma Prefectural Cardiovascular Center, Maebashi, Japan.

Yusuke Yoshikawa (Y)

Department of Biostatistics, National Cerebral and Cardiovascular Center, Suita, Japan.

Soshiro Ogata (S)

Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center, Suita, Japan.

Kunihiro Nishimura (K)

Department of Biostatistics, National Cerebral and Cardiovascular Center, Suita, Japan; Department of Preventive Medicine and Epidemiology, National Cerebral and Cardiovascular Center, Suita, Japan.

Yoshihiro Miyamoto (Y)

Department of Preventive Cardiology, National Cerebral and Cardiovascular Center, Suita, Japan.

Masaharu Ishihara (M)

Department of Cardiovascular and Renal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Shorter door-to-balloon time, better long-term...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Nécrose › Infarctus › Infarctus du myocarde › Infarctus du myocarde avec sus-décalage du segment ST › Shorter door-to-balloon time, better long-term...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Shorter door-to-balloon time, better long-term...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Shorter door-to-balloon time, better long-term...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Nécrose › Infarctus › Infarctus du myocarde › Shorter door-to-balloon time, better long-term...
questionsmedicales.fr › Procédures de chirurgie opératoire › Interventions chirurgicales mini-invasives › Procédures endovasculaires › Intervention coronarienne percutanée › Shorter door-to-balloon time, better long-term...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Shorter door-to-balloon time, better long-term...